Paolo Tarantino: Refresher for the current and upcoming definitions of HER2 in breast oncology

Paolo Tarantino shared on X/Twitter:

“Refresher for the current and upcoming definitions of HER2 in breast oncology: Table 1 from the ESMO – Eur. Oncology consensus on HER2-low matches each pattern of HER2 IHC expression with the conclusion by the ASCO/CAP guidelines and by the Consensus group.”

Visit the article website.
Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.